REPL
NASDAQ · Biotechnology
Replimune Group Inc
$4.07
+0.73 (+21.86%)
Open$3.32
Previous Close$3.34
Day High$4.18
Day Low$3.30
52W High$13.24
52W Low$1.50
Volume—
Avg Volume5.38M
Market Cap336.07M
P/E Ratio—
EPS$-3.44
SectorBiotechnology
Analyst Ratings
Strong Sell
13 analysts
Price Target
+773.5% upside
Current
$4.07
$4.07
Target
$35.55
$35.55
$27.68
$35.55 avg
$47.36
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |
| Rev Growth | -3.7% | +3.8% | +9.6% |
| Debt/Equity | 1.03 | 0.84 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |